NLS Pharma Shares Fall After Mazindol ER Interim Data Shows 39% Improvement On Sleepiness Scale

NLS Pharmaceutics Ltd NLSP has announced interim topline data from its Phase 2a trial of its lead product candidate, Quilience (Mazindol ER), in narcolepsy.
For excessive daytime sleepiness (EDS), the trial's primary endpoint, patients on Mazindol ER exhibited a mean decrease of 7.3 points on the sleepiness scale compared to a 3.0 point decrease for patients on placebo.
Patients on Mazindol ER showed a mean 39% improvement on the sleepiness scale from baseline.
To date, Mazindol ER was generally safe and well-tolerated in the current Phase 2a trial, and the interim data are consistent with prior mazindol studies.
Related: NLS Pharma Stock Gains After Issuance Of Mazindol US Patent.
No patients dropped out of the study due to safety or efficacy concerns, and only one patient in the interim analysis discontinued the study for personal reasons.
Study NLS-1022 (OLE study) to access treatment with Mazindol ER treatment for up to 6 months.
As of the data collection date for the Phase 2a interim analysis (February 25, 2022), 82% of patients who completed the randomized controlled study elected to participate in the OLE study.
Price Action: NLSP shares are down 32.70% at $1.19 during the market session on the last check Wednesday.